Oligonucleotide Drug Delivery Is Moving Beyond the Liver

Oligonucleotide drug delivery is expanding beyond the liver to target muscle, CNS, lungs, and immune cells, requiring tissue-specific strategies rather than universal solutions. Antibody conjugates, peptides, lipid nanoparticles, and targeted approaches are being developed for each tissue type, with delivery strategy significantly impacting downstream development, manufacturing, and scalability.